期刊文献+

质粒介导的组织激肽释放酶结合蛋白在肺癌相关细胞内的表达及其生物学活性研究 被引量:5

Plasmid-mediated expression of kallistatin and its biological activity in lung cancer related cells
原文传递
导出
摘要 研究裸质粒能否转染肺癌相关细胞,且有效表达具有血管形成抑制活性的组织激肽释放酶结合蛋白(Kal),以及Kal的表达对体内外肺癌及相关细胞的生物学影响。采用Lipofectamine 2000介导质粒对肺癌相关细胞的转染,ELISA法检测Kal浓度,并考察Kal对细胞增殖、凋亡和迁移的影响。瘤内直接注射质粒后,观察NCI-H446皮下移植瘤内CD34、Ki-67和E-钙黏蛋白水平变化,以及肿瘤细胞凋亡的情况。转染质粒后,所有受试细胞均可表达Kal,其中HUVEC的增殖和迁移受到抑制;3种肺癌细胞NCI-H446、NCI-H460和A549的增殖被不同程度地抑制,并出现凋亡现象。体内研究显示,Kal可以抑制新生血管生成及肿瘤细胞增殖,肿瘤生长速度显著降低。因此,可介导Kal表达的裸质粒可以作为肺癌治疗的候选药物。 This study is to investigate whether naked plasmid DNA can effectively transfect lung cancer related cells and express human kallistatin, an endogenous protein that inhibits angiogenesis and tumor growth, and to explore the biological activity of the low-level expressed kallistatin to lung cancer in vitro and in vivo. The plasmids were delivered with Lipofectamine 2000 to transfect various lung cancer related cells. Kal expression was determined by ELISA. The biological effects of Kal expression on proliferation, migration and apoptosis rate of the cells were examined. In subcutaneous NCI-H446 xenograft model, pKal was injected directly into tumors, the changes of CD34, Ki-67 and E-cadherin expression were detected with immunohistochemical assay, the tumor apoptosis was analyzed with TUNEL assay. Both the endothelial cell and lung cancer cells could express kallistatin after plasmid transfection. The proliferation and migration of human umbilical vein endothelial cells were inhibited, but the apoptosis rate was not affected. The proliferation rates of all the three tested lung cancer cells, such as NCI-H446, NCI-H460 and A549, were inhibited, and their apoptosis rates were enhanced, but different cells behaved differently. In subcutaneous NCI-H446 xenograft model, intratumor injection of pKal inhibited the growth of lung cancer by reducing angiogenesis and proliferation of tumor cells. In conclusion, this study demonstrated the efficacy of plasmid-mediated expression of kallistatin to lung cancer related cells, thus providing a basis for their clinical application in the treatment of lung cancer.
出处 《药学学报》 CAS CSCD 北大核心 2013年第3期359-365,共7页 Acta Pharmaceutica Sinica
基金 国家自然科学基金资助项目(30973591,81271691) 国际科技合作项目(2011DFG33320)
关键词 基因治疗 载体 组织激肽释放酶结合蛋白 新生血管形成 肺癌 gene therapy vector kallistatin angiogenesis lung cancer
  • 相关文献

参考文献6

二级参考文献59

  • 1陈长宝,青春,陆树良.siRNAs介导的基因沉默技术和相关应用的研究进展[J].上海第二医科大学学报,2005,25(11):1184-1187. 被引量:3
  • 2王薇,唐宁,张春玲,刘兴君,胡菡,张志翔,梁伟.细胞膜穿透肽促进脂质体包载的siRNA细胞内转运、定位及其功能[J].药学学报,2006,41(2):142-148. 被引量:6
  • 3[1]Hurwitz H,Fehrenbacher L,Novotny W,Cartwright T,Hainsworth J,Heim W,Berlin J,Baron A,Griffing S,Holmgren E,Ferrara N,Fyfe G,Rogers B,Ross R,Kabbinavar F.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer.N Engl J Med 2004; 350:2335-2342
  • 4[2]Jain RK,Duda DG,Clark JW,Loeffler JS.Lessons from phase Ⅲ clinical trials on anti-VEGF therapy for cancer.Nat Clin Pract Oncol 2006; 3:24-40
  • 5[3]Kisker O,Becker CM,Prox D,Fannon M,D'Amato R,Flynn E,Fogler WE,Sim BK,Allred EN,Pirie-Shepherd SR,Folkman J.Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.Cancer Res 2001;61:7669-7674
  • 6[4]Bergers G,Benjamin LE.Tumorigenesis and the angiogenic switch.Nat Rev Cancer 2003; 3:401-410
  • 7[5]Folkman J,Kalluri R.Cancer without disease.Nature 2004; 427:787
  • 8[6]Miao RQ,Agata J,Chao L,Chao J.Kallistatin is a new inhibitor of angiogenesis and tumor growth.Blood 2002; 100:3245-3252
  • 9[7]Li C,Bowles DE,van Dyke T,Samulski RJ.Adeno-associated virus vectors:potential applications for cancer gene therapy.Cancer Gene Ther 2005; 12:913-925
  • 10[8]Xu R,Sun X,Tse LY,Li H,Chan PC,Xu S,Xiao W,Kung HF,Krissansen GW,Fan ST.Long-term expression of angiostatin suppresses metastatic liver cancer in mice.Hepatology 2003; 37:1451-1460

共引文献53

同被引文献29

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部